Facebook
Twitter
LinkedIn
Forward
Discussing Evaporative Dry Eye: Updates on Diagnosis and New Treatments (CME/CE Podcast)
Activity Description and Purpose
Creating evidence-based treatment plans for patients with dry eye disease (DED) requires a nuanced understanding of the role of tear film evaporation in eye health. This podcast features discussions between Leslie E. O’Dell, OD, FAAO, and Lisa M. Nijm, MD, JD, on evaporation in DED, gland expression, and new treatments. The educational activity also includes a visual component for learners. With a focus on practical applications and real-world examples, this podcast equips clinicians with the knowledge and strategies to manage evaporative DED effectively. The desired results of this activity are to cement clinicians’ knowledge of the role of evaporation in the pathogenesis of MGD and help them obtain practical strategies for screening, diagnosis, and effective treatment that can improve patient outcomes.
Target Audience
This educational activity is intended for ophthalmologists and optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Incorporate diagnostic strategies that examine meibomian gland function in routine practice
- Design evidence-based treatment plans for persons with meibomian gland dysfunction–associated dry eye disease
Faculty
 | Leslie E. O’Dell, OD, FAAO |
 | Lisa M. Nijm, MD, JD |
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Lisa M. Nijm, MD, JD, is a consultant for Alcon, Allergan, Azura Ophthalmics, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Centricity Vision, Inc, Dompé US, Inc, Horizon Therapeutics plc, Iveric Bio, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, Trukera Medical, Visus Therapeutics, and Zeiss; is an advisory board member of Alcon, Allergan, Azura Ophthalmics, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Centricity Vision, Inc, Dompé US, Inc, Horizon Therapeutics plc, Iveric Bio, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Orasis Pharmaceuticals, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, Trukera Medical, and Zeiss; is on the speakers bureau for Allergan, Bausch & Lomb Incorporated, Horizon Therapeutics plc, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Ocular Therapeutix; and has stock options that have not been exercised in Trukera Medical.
Leslie E. O’Dell, OD, is a consultant for Alcon, Allergan, Bausch & Lomb Incorporated, Eye Eco Inc, Eyedetec Medical, Inc, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc; is on the speakers bureau for Aerie Pharmaceuticals, Inc*, Allergan, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; and has stock options that have not been exercised in Èssiri Labs and Eyedetec Medical, Inc.
* The financial relationship existed during the last 24 months but has now ended
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus and Amedco planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE approved for 0.5 CE credit for optometrists.
COPE Course ID: 86354-TD
COPE Course Category: Treatment/Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number 126651, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.
The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, State University of New York College of Optometry, or Bausch & Lomb Incorporated.
©2023 MedEdicus LLC. 302.1A
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 COPE
- 0.50 Participation